Linc 2021 12 Month Results Of The Acoart Btk Italy о Published: 26 jan 2021. dr francesco liistro (san donato hospital, arezzo, it) discusses the 12 month results of the acoart btk italy study. this study aims to assess the potential advantages of late lumen loss reduction of the litos drug eluting balloon vs standard percutaneous transluminal angioplasty, in the treatment of below the knee (btk. Selution slr. twelve month results from the prestige below the knee (btk) study have been presented as a late breaking trial at linc 2021 (the leipzig interventional course; 25–29 january, online).
Btk Dcb Dilatation Catheter 先瑞达医疗科技控股有限公司 Luminor dcb. in a late breaking trial session at linc 2021 (the leipzig interventional course, 25–29 january, online), key updates on below the knee (btk) interventions were in the spotlight. francesco liistro (azienda usl toscana sud est, arezzo, italy) presented nine month outcomes from the in.pact btk randomised study. January 28, 2021—medalliance announced that 12 month results from the prestige below the knee (btk) study were presented as a late breaking trial at linc 2021, the leipzig interventional course held as a virtual event january 25 29. the study sought to evaluate the safety and performance of the selution slr, the company’s sirolimus eluting. Nyon, switzerland, jan. 28, 2021 prnewswire 12 month results from the prestige* below the knee (btk) study have been presented as a late breaking trial at linc 2021. Presenting 12 month results of the acoart btk italy study, liistro noted their similarity to those of the acoart ii study, and concluded that the litos dcb “shows efficacy and safety in the.
Comments are closed.